Your shopping cart is currently empty

Lacto-N-tetraose is a core component of human milk oligosaccharides (HMOs) and is a tetrasaccharide composed of galactose, N-acetylglucosamine, and glucose. Lacto-N-tetraose exhibits a variety of biological activities, including prebiotic effects, immunomodulatory effects, anti-inflammatory effects, regulation of intestinal cell responses, as well as antibacterial and antiviral activities. Lacto-N-tetraose is widely used in infant formula, functional foods, and biomedical research.


| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $52 | - | In Stock | |
| 5 mg | $123 | - | In Stock | |
| 10 mg | $198 | - | In Stock | |
| 25 mg | $413 | - | In Stock | |
| 50 mg | $589 | - | In Stock |
| Description | Lacto-N-tetraose is a core component of human milk oligosaccharides (HMOs) and is a tetrasaccharide composed of galactose, N-acetylglucosamine, and glucose. Lacto-N-tetraose exhibits a variety of biological activities, including prebiotic effects, immunomodulatory effects, anti-inflammatory effects, regulation of intestinal cell responses, as well as antibacterial and antiviral activities. Lacto-N-tetraose is widely used in infant formula, functional foods, and biomedical research. |
| In vitro | Methods: Human peripheral blood lymphocytes (HPBL) were treated with Lacto-N-tetraose (250, 500, 1,000, 2,000 μg/mL) for 3 or 20 hours. Cytoplasmic fragmentation was assessed, and the CBPI and micronucleus rate were calculated. Results: Lacto-N-tetraose did not induce chromosomal breaks or aneuploidy. [1] |
| In vivo | Methods: Neonatal Sprague-Dawley rats were administered Lacto-N-tetraose (1,000, 2,500, 4,000 mg/kg/day) orally via gavage once daily starting at PND 7 for 90 days. Results: No adverse effects were observed at the highest dose of Lacto-N-tetraose (4,000 mg/kg/day), which was the maximum tolerated dose. [1] Methods: A constipation model was established in female BALB/c mice by intraperitoneal injection of loperamide (10 mg/kg), followed by oral gavage of Lacto-N-tetraose (450 mg/kg) once daily for 14 days. Results: Lacto-N-tetraose effectively improved gastrointestinal motility and bowel movements. [2] |
| Molecular Weight | 707.63 |
| Formula | C26H45NO21 |
| Cas No. | 14116-68-8 |
| Smiles | O([C@H]1[C@H](NC(C)=O)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O1)[C@@H]3[C@@H](O)[C@H](O[C@@H]([C@@H]([C@H](C=O)O)O)[C@@H](CO)O)O[C@H](CO)[C@@H]3O |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80.00 mg/mL (113.05 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.